Hervas 2001.

Clinical features and settings	Study period: n.r. Patient population: 20 patients with neuroblastoma with 47 ¹²³I‐MIBG scans. Consecutive series: n.r. Diagnostic work‐up: n.r. Time spans between symptoms and index test, between symptoms and reference standard and between index test and reference standard: n.r. Treatment between index test and reference standard: n.r.
Participants	Included patients: children with newly diagnosed neuroblastoma. Median age: n.r.; mean age: 4.4 years (SD 2.45). Sex distribution: 12 boys (60%), 8 girls (40%). INSS stage: two stage 1, three stage 2, three stage 3 and 12 stage 4.
Study design	Retrospective.
Target condition and reference standard(s)	Target condition: neuroblastoma. Reference standard: histology.
Index and comparator tests	Index test: ¹²³I‐MIBG scintigraphy. Radiofarmacon: ¹²³I‐MIBG. Dose: 3,7 MBq/Kg. Collimator: low energy. Matrix: n.r. Acquisition protocol: thorax, abdomen, lateral skull, and occasionally the extremities. Acquisition time: 3, 24, and 48 hours after injection. Acquisition duration: n.r. Interfering medication: n.r. Thyroid prophylaxis: n.r, Positive test result: when abnormal foci were observed (adrenal or extradrenals, or both) with increased uptake. Number and expertise of observers: n.r. Interobserver concordance: n.r.
Follow‐up	n.r.
Notes	Results n.r. for 20 patients with neuroblastoma at diagnosis separately from those during treatment. We could not get into contact with the authors.